BWV · Blue Water Biotech, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Revenue | $815.4K | $2.52M | $58.5K | - |
| Cost of Revenue | $182.5K | $1.47M | $1.19M | - |
| Gross Profit | $632.9K | $1.06M | ($1.13M) | - |
| R&D | - | $154.4K | $1.95M | $1.33M |
| SG&A | $7.04M | $11.23M | $9.35M | $2.09M |
| Total Operating Expenses | $18.49M | $57.54M | $34.91M | $3.42M |
| D&A | $15.2K | $731.3K | $43.9K | $4.9K |
| Operating Income | ($17.86M) | ($56.49M) | ($36.03M) | ($3.42M) |
| Interest Expense | $751.0K | $873.4K | $671.6K | - |
| Income Tax | $525 | ($1.05M) | ($12.6K) | $675.73B |
| Net Income | ($14.03M) | ($58.69M) | ($37.41M) | ($3.42M) |
| EPS - Basic | ($16.56) | ($21.45) | ($2.19) | ($1.26) |
| EPS - Diluted | ($16.56) | ($21.45) | ($2.19) | ($1.26) |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash & Equivalents | $5.22M | $646.5K | $4.55M | $25.75M |
| Accounts Receivable | $296.9K | $25.7K | $149.7K | - |
| Inventory | $150.0K | $64.1K | $364.1K | - |
| Accounts Payable | $1.76M | $3.79M | $5.30M | $1.50M |
| Current Assets | $6.07M | $950.3K | $5.84M | $26.26M |
| Total Assets | $24.93M | $28.18M | $87.52M | $26.31M |
| Current Liabilities | $9.14M | $18.29M | $17.19M | $3.92M |
| Long-term Debt | - | - | - | - |
| Total Liabilities | $9.16M | $18.57M | $21.88M | $1.64M |
| Stockholders' Equity | $15.76M | $8.54M | ($5.60M) | $22.39M |
| Retained Earnings | ($131.21M) | ($115.68M) | ($56.79M) | ($19.38M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Cash Flow | ($9.68M) | ($10.50M) | ($13.58M) | ($2.04M) |
| Investing Cash Flow | - | ($28.5K) | ($8.65M) | ($1.9K) |
| Financing Cash Flow | $14.45M | $6.74M | $1.04M | ($334.2K) |
| CapEx | - | $28.5K | $3.3K | $1.9K |
| Free Cash Flow | - | ($10.52M) | ($13.58M) | ($2.05M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Profitability | ||||
| Gross margin | 77.6% | 41.8% | -1927.9% | - |
| Operating margin | -2190.0% | -2238.0% | -61634.5% | - |
| EBITDA margin | -2188.2% | -2209.0% | -61559.3% | - |
| Net margin | -1721.0% | -2325.2% | -63986.5% | - |
| Free cash flow margin | - | -416.9% | -23235.0% | - |
| FCF / Net income | - | 0.18 | 0.36 | 0.60 |
| R&D / Revenue | - | 6.1% | 3334.3% | - |
| SG&A / Revenue | 863.9% | 445.0% | 15995.1% | - |
| Effective tax rate | - | - | - | 100.0% |
| Return on assets | -56.3% | -208.3% | -42.7% | -13.0% |
| Return on equity | -89.0% | -687.0% | 667.8% | -15.3% |
| Return on invested capital | - | - | - | - |
| Liquidity | ||||
| Current ratio | 0.66 | 0.05 | 0.34 | 6.69 |
| Quick ratio | 0.65 | 0.05 | 0.32 | 6.69 |
| Cash ratio | 0.57 | 0.04 | 0.26 | 6.57 |
| Leverage | ||||
| Debt / Equity | - | - | - | - |
| Debt / Assets | - | - | - | - |
| Debt / EBITDA | - | - | - | - |
| Interest coverage | -23.8x | -64.7x | -53.7x | - |
| Equity multiplier | 1.58 | 3.30 | -15.62 | 1.18 |
| Liabilities / Assets | 0.37 | 0.66 | 0.25 | 0.06 |
| Efficiency | ||||
| Asset turnover | 0.03 | 0.09 | 0.00 | - |
| Inventory turnover | 1.22 | 22.93 | 3.26 | - |
| Days sales outstanding | 133d | 4d | 935d | - |
| Days inventory outstanding | 300d | 16d | 112d | - |
| Days payable outstanding | 3516d | 941d | 1630d | - |
| Cash conversion cycle | -3083d | -921d | -583d | - |
| Valuation | ||||
| P / E | - | - | - | - |
| P / B | - | - | - | - |
| P / S | - | - | - | - |
| EV / EBITDA | - | - | - | - |
| Growth | ||||
| Revenue growth (YoY) | -67.7% | 4217.3% | - | - |
| Revenue CAGR (3y) | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - |
| Gross profit growth (YoY) | -40.0% | - | - | - |
| Operating income growth (YoY) | 68.4% | -56.8% | -954.5% | - |
| Net income growth (YoY) | 76.1% | -56.9% | -994.7% | - |
| EPS growth (YoY) | 22.8% | -879.5% | -73.8% | - |
| EPS CAGR (3y) | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - |
| FCF growth (YoY) | - | 22.5% | -563.9% | - |
| FCF CAGR (5y) | - | - | - | - |
| Book value growth (YoY) | 84.5% | - | - | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$796.6K totalOther Revenues$587.9K · 73.8%
Product Sales$207.1K · 26.0%
Development Service$1.7K · 0.2%
License$1 · 0.0%
Geographic
$1.63M totalCH$796.6K · 48.8%
European Union$796.6K · 48.8%
GB$18.8K · 1.2%
Non European Union$18.8K · 1.2%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
-6.02
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
5/9
Neutral
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✓No share dilution
- ✓Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Blue Water Biotech against the 5 most active filers in the same SIC group.